Tube-wrapped lamp makes malaria drug


20 January 2012

German researchers have developed an inexpensive three-step continuous flow synthesis of artemisinin, the key drug in the ongoing fight against malaria. François Lévesque and Peter Seeberger from the Max Planck Institute for Colloids and Interfaces in Potsdam say that their approach could supplement existing production, improving the drug's availability.  

Flow reactor
After only four and a half minutes in the flow reactor, artemisinic acid is converted into artemisinin

© Ulrich Kleiner
Seeberger tells Chemistry World that yields of artemisinin made using this technique have already increased from when the paper was first published. At that point yields were 200g of artemisinin per day per reactor, but now stand at 800g. 'We are about three months away from being able to conduct it on a 2kg per day scale,' Seeberger adds. 'If you take that number, then you need approximately 150 reactors to make the entire world's supply for a year. And we have reduced the cost of the equipment. The one we described is about €50,000 (£42,000). We've got the price down to about €10,000 now.'     

Artemisinin is the most effective therapy in the fight against the plasmodium parasites responsible for more than 200 million cases of malaria each year. Currently, the drug is extracted from sweet wormwood plants. This means that supplies of artemisinin are limited. And its fused ring structure with an endoperoxide group, which gives it its killing power, makes synthesising it from scratch impractical. Consequently, Seeberger and Lévesque instead began their synthesis from artemisinic acid, a by-product generated by current artemisinin production in quantities up to 10 times the mass of the drug. It can also be produced by genetically-engineered yeast.  

Antimalarial drugs scheme1

Photochemically produced singlet oxygen aids the conversion of artemisinic acid to the drug artemisinin

© Angew. Chem., Int. Ed.

The two chemists began by reducing artemisinic acid to dihydroartemisinic acid, prior to the critical synthetic step of reacting it with singlet oxygen to form a hydroperoxide. The highly reactive singlet oxygen molecule must be produced by a photochemical reaction. This can trouble large-scale manufacturing, as light only penetrates a limited distance into batch reactors. However, by pumping reagents continuously through tubes wrapped around a lamp, Seeberger and Lévesque could illuminate the entire solution efficiently. 

Martyn Poliakoff, at University of Nottingham, UK, who has also investigated singlet oxygen flow chemistry, calls the artemisinin synthesis 'an elegant piece of work'. 'I hope it will promote interest in continuous flow reactions and photochemistry,' he commented. 'I also hope it will lead to more widely available treatments for malaria.'  

Seeberger shares a similar outlook, with a spin-out company based on the technology in the pipeline. 'I'm very excited about the prospect of being able to get this to the people who need it,' he says.  

Andy Extance

 

Interesting? Spread the word using the 'tools' menu on the left

References

F Lévesque and P H Seeberger, Angew. Chem., Int. Ed.,  2012, DOI: 10.1002/anie.201107446 

Also of interest

Profile: Modernizing traditional Chinese medicine

Modernizing traditional Chinese medicine


Cultivating the seeds of hope

Cultivating the seeds of hope

There are 250 million cases of malaria each year, and effective medication is expensive and in short supply. Justine Davies explores possible solutions


Boosting the flow in pharma's pipelines

Flow chemistry is poised to become an important tool for new drug development


NEWS-p6-67

Boom and bust for antimalarial industry

19 December 2007

China's artemisinin producers face market collapse


Related Links

Link icon Comment on this story at the Chemistry World blog
Read other posts and join in the discussion


External links will open in a new browser window